All In Biotech

Drug Trial Radar · NCT07794475

Effect of Trimetazidine on Endothelin-1 and Clinical Outcomes of Patients With Diabetic Peripheral Neuropathy

Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 1, 2026

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
Sara Refaat Azab MetryAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to investigate if trimetazidine can improve clinical outcomes of patients with diabetic peripheral neuropathy. The main questions it aims to answer are: Does trimetazidine improve the symptoms of diabetic peripheral neuropathy? Does trimetazidine affect endothelin-1 levels? Participants in the interventional arm will receive trimetazidine tablets 35 mg twice daily for three months.

Conditions

  • Diabetic Peripheral Neuropathic Pain (DPN)

Interventions

  • Trimetazidine Dihydrochloride TabletsDrug

    trimetazidine 35 mg oral tablets twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Endothelin-1 levelsTime frame: at baseline assessment and at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute of Diabetes

    Cairo, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.